Pharmaron Beijing Co (STU:17Q1) Interest Expense : €-28 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Pharmaron Beijing Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Pharmaron Beijing Co's interest expense for the three months ended in Mar. 2025 was € -6 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2025 was €-28 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Pharmaron Beijing Co's Operating Income for the three months ended in Mar. 2025 was € 57 Mil. Pharmaron Beijing Co's Interest Expense for the three months ended in Mar. 2025 was € -6 Mil. Pharmaron Beijing Co's Interest Coverage for the quarter that ended in Mar. 2025 was 10.15. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pharmaron Beijing Co Interest Expense Historical Data

The historical data trend for Pharmaron Beijing Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Interest Expense Chart

Pharmaron Beijing Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-3.00

-11.54

-22.66

-23.40

-31.97

Pharmaron Beijing Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Expense	Get a 7-Day Free Trial															-9.02	-8.67	-7.03	-6.60	-5.60

Pharmaron Beijing Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-28 Mil.

Pharmaron Beijing Co (STU:17Q1) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pharmaron Beijing Co's Interest Expense for the three months ended in Mar. 2025 was €-6 Mil. Its Operating Income for the three months ended in Mar. 2025 was €57 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2025 was €604 Mil.

Pharmaron Beijing Co's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2025 )	/	Interest Expense (Q: Mar. 2025 )
	=	-1	*	56.848	/	-5.599
	=	10.15

The higher the ratio, the stronger the company's financial strength is.

Pharmaron Beijing Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (STU:17Q1) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

03759:Hong Kong 300759:China

Address

No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Wanchai, Hong Kong, HKG

Website

https://www.pharmaron.com

Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. The company's operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.

Pharmaron Beijing Co Headlines

No Headlines